Literature DB >> 24916180

Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.

K Bell1, N Hodgson, M Levine, B Sadikovic, K Zbuk.   

Abstract

To report on a highly unusual case of a 20-year-old woman who presented with multifocal metaplastic breast cancer and was subsequently found to carry deleterious germline mutations in both BRCA1 and p53. Genetic testing was requested on an expedited basis to assist in surgical decision-making and BRCA1/2 and p53 genetic analysis was ordered concurrently. BRCA1/2 and p53 analyses were completed using a combination of direct DNA sequencing and multiplex ligation probe amplification (MLPA). The patient was found to carry a deletion of exon 3 of the BRCA1 gene and a splice site mutation at the exon4/intron4 boundary of the p53 gene. To our knowledge, this is the first report of double heterozygosity in BRCA1 and p53. The patient's clinical presentation is highly reminiscent of that predicted by preclinical mouse models. In patients with early onset breast cancer, the possibility of germline mutations in more than one cancer susceptibility gene should be considered. This could have important clinical implications for patients and their at-risk family members.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24916180     DOI: 10.1007/s10549-014-3011-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  A Rare Case of Breast Malignancy in an Adolescent Woman: Lessons Learned from Diagnosis and Management.

Authors:  Célina Alexandra Fehr; Philip Went; Martina Maranta; Richard Cathomas
Journal:  Breast Care (Basel)       Date:  2020-12-16       Impact factor: 2.268

2.  Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.

Authors:  Hagit Shani; Rinat Bernstein-Molho; Yael Laitman; Iris Netzer; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2021-01-15       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.